Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
New Data Show Longer Tysabri Dosing Interval in MS Is Feasible
Direct and indirect cost burden associated with multiple sclerosis relapses: Excess costs of persons with MS and their spouse caregivers.
Improvement of interferon-beta related skin reactions after diluent halving: first experience of five patients.
Acute Disseminated Encephalomyelitis Associated With Acute Toxoplasma gondii Infection.
Neuroradiological evaluation of demyelinating disease.
Selection and optimization of therapy for progressive type multiple sclerosis.
Apitope starts new clinical trial of its investigational Multiple Sclerosis treatment
Epigenetics in NG2 glia cells.
The hepatocyte growth factor (HGF)-MET receptor tyrosine kinase signaling pathway: Diverse roles in modulating immune cell functions.
A mechanism-based classification of pain in multiple sclerosis.
[Efficacy and tolerability of long-term using of glatimer acetate (copaxone): a 10 year-study in the Moscow Municipal Multiple Sclerosis center.]
The role of angiogenesis in the pathology of multiple sclerosis.
Natalizumab Treatment Reduces Fatigue in Multiple Sclerosis. Results from the TYNERGY Trial; A Study in the Real Life Setting.
Assessment of definitions of sustained disease progression in relapsing-remitting multiple sclerosis.
Prevalence and concurrence of anxiety, depression and fatigue over time in multiple sclerosis.
Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI.
Study protocol: To investigate effects of highly specialized rehabilitation for patients with multiple sclerosis a randomized controlled trial of a personalized, multidisciplinary intervention.
Agent based modeling of Treg-Teff cross regulation in relapsing-remitting multiple sclerosis.
[The process of meaning-making in adjustment to multiple sclerosis.]
Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice.
Disruption of nodal architecture in skin biopsies of patients with demyelinating neuropathies.
Medical and Nonstroke Neurologic Causes of Acute, Continuous Vestibular Symptoms.
Extremely low-frequency pulsed magnetic fields and multiple sclerosis: effects on neurotransmission alone or also on immunomodulation? Building a working hypothesis.
Neurons and T cells: Understanding this interaction for inflammatory neurological diseases.
A modified superantigen rescues Ly6G(-)CD11b(+)blood monocyte suppressor function and suppresses antigen-specific inflammation in EAE.
Pages
« first
‹ previous
…
279
280
281
282
283
284
285
286
287
…
next ›
last »